The first dosing of TEW-7197 in a cancer patient in the USA

Aug 05, 2014EVENTSHit 1709

 MedPacto, Inc. has finished the first dosing of TEW-7197 in human on 4th of August, 2014 in Nashville, USA. (NCT02160106) TEW-7197 is the forefront asset of Medpacto's oncology pipeline and it is for cancer patients of solid tumors. The phase I trial is planned to be completed in April of 2016 and its interim analysis after a phase of dose escalation is expected to be conducted in the middle of 2015.

About TEW-7197
 TEW-7197 is an inhibitor of ALK5 (TGF-beta receptor 1) which is a small molecule for oral formulation. It blocks TGF-beta signaling efficiently and it showed an excellent profile of safety and potency in non-clinical studies. It has a potential for the best-in-class oncology drug in its class. The development of TEW-7197 was supported by Program for Disease-Based Discovery of Global New Drug Candidates and its clinical development is supported by National OncoVenture (NOV), National Cancer Center, Korea.

Next Temporary meeting of the board of directors
Previous Clinical trial of TEW-7197 starts its first step.